Baxter (NYSE:BAX) announced today that it recieved FDA clearance for its next-generation artificial kidney 98 (AK 98) dialysis machine.
Deerfield, Ill.-based Baxter’s AK 98 machine is designed as a portable and easy-to-use system to administer hemodialysis (HD) treatments.
It offers encrypted, two-way connectivity to enable the system to pull prescriptions directly from the electronic medical record for simplified workflow and data handling, according to a news release.
AK 98 includes features such as automatic alert resolution, which enables the machine to self-clear already corrected pressure alarms and avoid the unnecessary stoppage of treatment. Additionally, an intuitive customizable interface, a simple set-up process and a stable base design comprise the machine.
“We designed this latest version of our AK 98 system to help dialysis providers minimize the operational challenges that can come with administering multiple hemodialysis sessions per machine per day,” Gavin Campbell, GM of Baxter’s U.S. renal care business, said in the release. “With our recent De Novo authorization of Theranova, our novel dialysis membrane, our latest innovations to support HD provide our customers with choices for therapy and treatment modality.”